🇺🇸 Supernus Pharmaceuticals, Inc.
Forum topic · SUPN · Company page: financials, ownership and filings
Join the discussion on Supernus Pharmaceuticals, Inc.
Loading…
Reported to the SEC: Change in control
Supernus Pharmaceuticals, Inc. reported on 2 November 2026 (SEC Form 8-K):
• Change in control: Control of the company changed hands.
This is the SEC's classification of the filing; the filing itself has the details.
Reported to the SEC: Delisting notice
Supernus Pharmaceuticals, Inc. reported on 2 November 2026 (SEC Form 8-K):
• Delisting notice: The exchange told the company it no longer meets a listing rule, or the company is moving or leaving its listing (takeovers are counted separately).
This is the SEC's classification of the filing; the filing itself has the details.
Results announced on 29 October 2026
Supernus Pharmaceuticals, Inc. announced results on 29 October 2026 (SEC Form 8-K, item 2.02).
For the quarter ended 30 September 2026: revenue of $227 million (up 18% from a year earlier) and net income of $21 million.
Results announced on 19 October 2026
Supernus Pharmaceuticals, Inc. announced results on 19 October 2026 (SEC Form 8-K, item 2.02).
For the quarter ended 30 September 2026: revenue of $227 million (up 18% from a year earlier) and net income of $21 million.
Mutual funds: 290 funds hold $1.2 billion
290 mutual funds in 2 countries hold shares of Supernus Pharmaceuticals, Inc. worth $1.2 billion, about 44.4% of the company (funds' newest reports, up to 31 July 2026).
Since their previous reports 144 funds added shares and 106 sold; on balance they bought $7 million. Share splits are not counted as trading.
Source: Automatic updates: SEC filings, regulators' notices and fund reports held on this site. Posts marked 🤖 are written automatically from official data and state no opinion. Member comments are their authors' views, shown after an editor's review; they are not investment advice.